{
      "Rank": 854,
      "Acronym": [
            "MSC11FCD-GBM"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "The investigational drug in the amount of 1x10^7, 3x10^7cells per dose into the tumor or the tumor removal site using a syringe during surgery"
      ],
      "ArmGroupInterventionName": [
            "Drug: MSC11FCD"
      ],
      "ArmGroupLabel": [
            "The investigational drug into the Intratumoral administration"
      ],
      "ArmGroupType": [
            "Other"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04657315"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This is a phase I trial evaluating the maximum tolerated dose, safety and efficiency of Mesenchymal stem cells into which the suicide gene, cytosine deaminase (CD), injected into the resection cavity of patients with recurrent glioblastoma."
      ],
      "BriefTitle": [
            "Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "Ajou University School of Medicine"
      ],
      "CompletionDate": [
            "December 31, 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Glioblastoma",
            "Adult Gliosarcoma",
            "Neoplasms, Brain",
            "Neoplasms, Germ Cell and Embryonal",
            "Recurrent Glioblastoma"
      ],
      "ConditionAncestorId": [
            "D000020969",
            "D000010335",
            "D000001254",
            "D000005910",
            "D000018302",
            "D000017599",
            "D000009370",
            "D000009375",
            "D000009380",
            "D000016543",
            "D000009423",
            "D000009371",
            "D000001927",
            "D000002493",
            "D000009422"
      ],
      "ConditionAncestorTerm": [
            "Disease Attributes",
            "Pathologic Processes",
            "Astrocytoma",
            "Glioma",
            "Neoplasms, Neuroepithelial",
            "Neuroectodermal Tumors",
            "Neoplasms by Histologic Type",
            "Neoplasms, Glandular and Epithelial",
            "Neoplasms, Nerve Tissue",
            "Central Nervous System Neoplasms",
            "Nervous System Neoplasms",
            "Neoplasms by Site",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Nervous System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC04",
            "BC10",
            "All",
            "BC23",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Neoplasms",
            "Nervous System Diseases",
            "All Conditions",
            "Symptoms and General Pathology",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Neoplasms, Brain",
            "Recurrent",
            "Glioblastoma",
            "Neoplasms, Germ Cell and Embryonal",
            "Gliosarcoma",
            "Glioblastoma",
            "Gliosarcoma"
      ],
      "ConditionBrowseLeafId": [
            "M4361",
            "M14002",
            "M8171",
            "M11470",
            "M11519",
            "M18089",
            "M19613",
            "M21853",
            "M3713",
            "M8172",
            "M19599",
            "M18997",
            "M19540",
            "M11467",
            "M11472",
            "M11477",
            "M4356",
            "M4894",
            "T2518",
            "T2522",
            "T2519",
            "T4092"
      ],
      "ConditionBrowseLeafName": [
            "Brain Neoplasms",
            "Recurrence",
            "Glioblastoma",
            "Neoplasms, Germ Cell and Embryonal",
            "Nervous System Neoplasms",
            "Central Nervous System Neoplasms",
            "Gliosarcoma",
            "Disease Attributes",
            "Astrocytoma",
            "Glioma",
            "Neoplasms, Neuroepithelial",
            "Neuroectodermal Tumors",
            "Neuroectodermal Tumors, Primitive",
            "Neoplasms by Histologic Type",
            "Neoplasms, Glandular and Epithelial",
            "Neoplasms, Nerve Tissue",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Glioblastoma",
            "Gliosarcoma",
            "Glioma",
            "Neuroepithelioma"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000009369",
            "D000005909",
            "D000018316",
            "D000009373",
            "D000001932",
            "D000012008"
      ],
      "ConditionMeshTerm": [
            "Neoplasms",
            "Glioblastoma",
            "Gliosarcoma",
            "Neoplasms, Germ Cell and Embryonal",
            "Brain Neoplasms",
            "Recurrence"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Not Provided"
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatients aged 19 to 70\nPatients diagnosed with recurrent glioblastoma based on medical imaging after receiving standard therapy for glioblastoma\nPatients scheduled to undergo surgical treatment for recurrent glioblastoma\nPatients diagnosed with recurrent glioblastoma based on medical imaging (MRI: conventional, diffusion, perfusion, spectroscopy) and confirmed to have tumor cells during surgery based on frozen biopsy\nPatients whose expected survival period is at least 3 months\nPatients who have not received any other types of immunotherapy\nPatients who have been given a sufficient explanation of the purpose and details of the clinical trial and the characteristics of the investigational drug from an investigator and who signed the consent form or had a legal guardian or representative sign the consent form prior to the beginning of this clinical trial\nPatients who have waited for at least four weeks after treatment using cytotoxic drugs in order to eliminate the possibility of impact and effects from other therapeutic agents (23 days after the last administration in case of undergoing standard therapy using temozolomide)\n\nExclusion Criteria:\n\nPatients who have primary glioblastoma\nPatients with dihydropyrimidine dehydrogenase (DPD) deficiency\nPatients who cannot undergo a contrast (gadolinium) enhanced MRI scan due to a certain condition (pacemaker, etc.) or cannot undergo an MRI scan according to the clinical trial schedule due to any other reasons\nPatients to whom Gliadel water was applied during surgery\nPatients who are deemed to have a serious dysfunction in any of the major organs (liver, kidneys, bone marrow, lungs, heart) by the investigator\nPatents who have other types of malignant tumor aside from glioblastoma or who have had malignant tumor in the past 5 years\nPatients who uncontrolled hypotension or hypertension\nDiabetic patients who are currently receiving insulin therapy or who need insulin therapy\nPatients who are deemed to have a serious infectious disease by the investigator: sepsis, hepatitis A, hepatitis B or hepatitis C (in the case of hepatitis B and C viruses, however, carriers may be enrolled at the investigator's discretion) or tested positive in a serological test for the human immunodeficiency virus (HIV)\nKarnofsky Performance Scale < 60\nPatients with an autoimmune disease affecting the central nervous system (multiple sclerosis, myasthenia gravis, acute disseminated encephalomyelitis, etc.)\nPatients with a history of allergic reactions to flucytosine (5-FC) and/or its excipients or 5-fluorouracil (5-FU)\nPregnant or lactating women or patients who plan on getting pregnant during the clinical trial or refuses to choose an appropriate method of contraception\nPatients who have participated in a different clinical trial no more than 30 days prior to registering for this clinical trial\nPatients who are deemed to be unfit for this clinical trial by the investigator"
      ],
      "EnrollmentCount": [
            "10"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "The investigational drug into the Intratumoral administration"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M7717"
      ],
      "InterventionBrowseLeafName": [
            "Flucytosine"
      ],
      "InterventionBrowseLeafRelevance": [
            "low"
      ],
      "InterventionDescription": [
            "Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10^7, 3x10^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery.\n\nConcomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day\n\nDirections:\n\nAdministration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery.\n\nRoute of administration: Oral administration"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "MSC11FCD"
      ],
      "InterventionOtherName": [
            "Mesenchymal stem cells into which the suicide gene, cytosine deaminase (CD)"
      ],
      "InterventionType": [
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Glioblastoma, Mesenchymal stem cells",
            "Brain Tumor",
            "Neoplasms, Germ Cell",
            "Flucytosine",
            "Central Nervous System Neoplasms"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "January 11, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "January 6, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "CHA University"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Seongnam"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Korea, Republic of"
      ],
      "LocationFacility": [
            "Bundang CHA Medical Center"
      ],
      "LocationState": [
            "Kyunggido"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "13496"
      ],
      "MaximumAge": [
            "70 Years"
      ],
      "MinimumAge": [
            "19 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Investigator-initiated and Open-labeled Clinical Trial for Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "CHA University"
      ],
      "OrgStudyId": [
            "CHAMC 2019-08-022"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "CHA University"
      ],
      "OverallOfficialName": [
            "Kyunggi Cho, MD,PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Enrolling by invitation"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 31, 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Assessment of the maximum tolerated dose based on the 3+3 method\n\nBlood concentrations of 5-FC and 5-FU(Day 1, Day 3, Day 7)\nMSC11FCD concentrations (MSCCD detection) (Day 0, 3months, 6months, 12months)",
            "Evaluate the number of adverse event related to the treatment according to CTCAE V4.0 during the trial (including clinically significant changes in physical examination, radiographic images, safety lab tests, vital signs)"
      ],
      "PrimaryOutcomeMeasure": [
            "Maximum tolerated dose (MTD)",
            "Number Of Adverse Events related to the treatment"
      ],
      "PrimaryOutcomeTimeFrame": [
            "after treatment discontinuation for approximately 1 years",
            "Baseline, Day0, 1 month, 3 months, 6 months, 12 months"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "CHA University"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Kyung GI, CHO"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Professor"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "OS is defined as the time from the date of MSC injection to the date of death due to any cause.",
            "The progress-free survival analysis shall be based on the RANO criteria.",
            "Assess the treatment groups participating in this clinical trial based on the RANO criteria.\n\nCompare and present the disease control rates by calculating the ratio of the number of subjects responding to treatment (complete response: CR, partial response: PR, stable disease: SD) among the treatment groups and control group assessed based on the RANO criteria.",
            "Karnofsky performance status (KPS) assessment"
      ],
      "SecondaryOutcomeMeasure": [
            "Overall Survival improvement (OS)",
            "Progression Free Survival (PFS)",
            "Tumor assessment in regard to the investigational drug based on the RANO criteria",
            "Clinical efficacy assessment"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Study entry through the end of the study, up to 12 months",
            "Study entry through the end of the study, up to 12 months",
            "At Baseline, 1month, 3months, 6months, 12months",
            "At Baseline, 1month, 3months, 6months, 12months"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "June 24, 2020"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "January 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "December 8, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "November 1, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "December 5, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}